Track Fate Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Fate Therapeutics, Inc. FATE · Stock Open Fate Therapeutics, Inc. in new tab

1.28 USD
EPS
-1.03
P/B
0.89
ROE
-60.75
Beta
2.67
Target Price
5.72 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-1.03
Book Value1.80
Price to Book0.89
Debt/Equity49.32
% Insiders1.065%
Growth
Revenue Growth0.09%
Estimates
Forward P/E-1.62
Forward EPS-0.99
Target Mean Price5.72

DCF valuation

Model fair value for Fate Therapeutics, Inc. (FATE)
Result
Sign in to run the valuation for FATE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Buy · mean target 5.72 USD (low 2.50, high 8.00) · as of 12 Nov 2026
Low 2.50
Mean 5.72
High 8.00
Price 1.28
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Fate Therapeutics, Inc. Logo Fate Therapeutics, Inc. Analysis (FATE)

United States Health Care Official Website Stock

Is Fate Therapeutics, Inc. a good investment? Fate Therapeutics, Inc. (FATE) is currently trading at 1.28 USD. Market analysts have a consensus price target of 5.72 USD. This suggests a potential upside from current levels.

Earnings Schedule: Fate Therapeutics, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -0.99.

Investor FAQ

Does Fate Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Fate Therapeutics, Inc.?

Fate Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -1.03.

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Exchange Ticker
NMS (United States) FATE
FRA (Germany) F6T.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion